Drugs and Devices

FDA approves Osphena for postmenopausal women with dyspareunia

On Feb. 26, 2013, the U.S. Food and Drug Administration (FDA) approved Osphena (ospemifene) to treat women with moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy caused by menopause. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares